Promising Results for B7-H3 Antibody-Drug Conjugate in Advanced Solid Tumors (including metastatic castration resistant prostate cancer)
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxMetformin Shows Promise in Reducing Side Effects of Hormone Therapy in Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxJanux Therapeutics Announces 100% Response in Phase 1a Results for JANX007 in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxTruqap Shows Promise in Treating a Subtype of Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxFDA Accepts Darolutamide Plus ADT sNDA for mHSPC Treatment
/0 Comments/in Clinical Trial, FDA approvals, Metastatic, Phase 3/by MaxPhase III Trial for Metastatic Castration-Resistant Prostate Cancer of an EZH2 inhibitor
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxAMPLITUDE phase 3 Study for Metastatic Castration-Sensitive Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 2 trial: Delaying Systemic Treatment in Metastatic Prostate Cancer – A New Approach
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxTags
abiraterone acetate ADC ADT androgen deprivation therapy antibody-drug conjugate apalutamide ATM bispecific antibody cancer cancer immunotherapy cancer treatment CAR-T castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology PARP inhibitor PEACE-1 personalized medicine prostate cancer PSA response PSMA radioligand therapy real-world data small molecule survival outcomes T-cell therapy targeted drug delivery theranostics tumor microenvironment
Latest Posts
- Newsletter 3/2025 January 19, 2025
- PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair January 18, 2025
- Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025 January 17, 2025
- UMass Scientists Develop Novel Bacteria-Based Cancer Therapy January 16, 2025